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Glycogen synthase kinase-3 (GSK-3) unique position inmodulating the function of a diverse series of proteins in combinationwith
its association with a wide variety of human disorders has attracted significant attention to the protein both as a therapeutic target
and as a means to understand the molecular basis of these disorders. GSK-3 is ubiquitously expressed and, unusually, constitutively
active in resting, unstimulated cells. In mammals, GSK-3α and β are each expressed widely at both the RNA and protein levels
although some tissues show preferential levels of some of the two proteins. Neither gene appears to be acutely regulated at the
transcriptional level, whereas the proteins are controlled posttranslationally, largely through protein-protein interactions or by
posttranslational regulation. Control of GSK-3 activity thus occurs by complex mechanisms that are each dependent upon specific
signalling pathways. Furthermore, GSK-3 appears to be a cellular nexus, integrating several signalling systems, including several
secondmessengers and a wide selection of cellular stimulants. This paper will focus on the diﬀerent ways to control GSK-3 activity
(phosphorylation, protein complex formation, truncation, subcellular localization, etc.), the main signalling pathways involved in
its control, and its pathological deregulation.
1. Introduction
Glycogen synthase kinase-3 (GSK-3) is a CMGC serine/
threonine protein kinase initially described as one of the
kinases that phosphorylates and inhibits glycogen synthase
[1]. It is now widely accepted though that GSK-3 plays an
important role in various essential physiological processes,
such as development, cell cycle, or apoptosis [2]. Apart from
glycogen synthase, a plethora of diﬀerent substrates has been
identified in all cellular compartments, that is, metabolic
proteins [3], cytoskeletal proteins [4], and transduction [5]
and transcription factors [6] (see Table 1).
In neuronal development, GSK-3 has been reported to
control morphogenesis and axonal polarity [7], synaptogen-
esis [8], and survival [9, 10]. In addition, GSK-3 dysfunction
has been associated with brain pathological conditions, such
as Alzheimer’s disease (AD) [11, 12] or prion neurotoxicity
[13]. Thus, the deep knowledge of the role of both GSK-3
isoforms in brain metabolism will allow us to understand
their contribution to neurodegenerative processes.
GSK-3 unique position in modulating the function of a
diverse series of proteins in combination with its association
with a wide variety of human disorders has attracted
significant attention to the protein both as a therapeutic
target and as a means to understand the molecular bases of
these disorders. Furthermore, GSK-3 appears to be a cellu-
lar nexus, integrating several signalling systems, including
numerous second messengers and a wide selection of cellular
stimulants.
2. GSK-3 Structure
GSK-3 has been highly conserved during evolution, and
homolog genes have been identified in virtually every
eukaryotic genome investigated, including species, such
as Dictyostelium discoideum, Xenopus laevis, or Drosophila
melanogaster [14–16]. Inmammals, GSK-3 is encoded by two
genes known as gsk-3α and gsk-3β [17, 18] encoding GSK-
3α (483 aa in humans) and GSK-3β (433 aa) proteins with
apparent molecular masses of 51 and 47 kDa, respectively.
Both isoforms are almost identical (98%) within their ATP
binding pocket but diﬀer at their N- and C-terminal domains
[19]. A neuron-specific splicing isoform (β2) having an
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Table 1: GSK-3 substrates.
Metabolic proteins Structural proteins
Transcription
factors
Glycogen synthase Tau AP-1
ATP cytrate lyase MAP1B β-catenin
PKA MAP2 CREB
PDH NCAM C/EBP
Acetyl-CoA
carboxylase
Neurofilaments Myc
PP1 CRMP2 NFκB
PP2A inhibitor Dynein NFAT
PP2A
Dynamin-like
protein
GR
Cyclin D1 MBP HSF-1
eIF2B APC Notch
NGF receptor Kinesin light chain p53
Axin HIF-1
APP
Bax
VDAC
Hexokinase
Presenilin
LRP5/6
Substrate
S/T XXXS/T
GSK-3
P P
GSK3 Selectivity
insertion of 13 aa within the substrate-binding domain has
also been described [20]. Mammalian GSK-3α and β are each
widely expressed although some tissues show preferential
levels of some of the two proteins. Neither gene appears to
be acutely regulated at the transcriptional level.
Crystallographic studies have revealed the three-
dimensional structure of GSK-3β [21, 22]. Its overall
shape is shared by all kinases, with a small N-terminal
lobe mostly consisting of β-sheets and a large C-terminal
lobe essentially formed of α-helices [23]. The ATP binding
pocket is located between the two lobes and although,
is well conserved among kinases [24], it is possible to
obtain selective inhibitors by taking advantage of the small
diﬀerences that exist between the diﬀerent kinases. Current
availability of crystal structures of complexes of GSK-3β
with a variety of ligands, together with molecular modelling
approaches, provides the necessary clues for enhancing
selectivity towards GSK-3 [22].
Some GSK-3 substrates do not require a very specific
sequence, but rather a previous (primed) phosphorylation
by a priming kinase on a Ser or Thr residue located four
aminoacids, C-terminal to the Ser or Thr residue to be
modified by GSK-3 (see below for regulation through primed
phosphorylation). The crystal structure of human GSK-3β
has provided a model for the binding of prephosphorylated
substrates to the kinase. According to it, primed Ser/Thr is
recognized by a positively charged binding pocket formed
by residues Arg96, Arg180, and Lys205 that facilitates the
binding of the phosphate group of primed substrates. GSK3β
uses the phosphorylated serine or threonine at position +4 of
the substrate to align of the two domains for optimal catalytic
activity [21, 22].
Furthermore, crystal structures of GSK-3β complexes
with interacting proteins FRAT/GBP and axin have allowed
defining the molecular basis for those interactions, which
play critical role in some signalling pathways (see below
for regulation through protein complex formation). These
studies confirm the partial overlap of the binding sites of axin
and FRAT1/GBP predicted from genetic and biochemical
studies [2, 25] but reveal significant diﬀerences in the
detailed interactions and identify key residues mediating the
diﬀerential interaction with both proteins. This ability of
GSK-3β to bind two diﬀerent proteins with high specificity
via the same binding site is mediated by the conformational
plasticity of the 285–299 loop, while some residues in this
versatile binding site are involved in interactions with both
axin and FRAT; others are involved uniquely with one or the
other [26].
3. How Is GSK-3 Activity Controlled?
As already mentioned above, one of the main characteristics
of GSK-3 is that its activity is high in resting, unstimulated
cells while regulated by extracellular signals that typically
induce a rapid and reversible decrease in enzymatic activity.
Glycogen synthase kinase-3 is a dual specificity kinase
diﬀerentially regulated by tyrosine and serine/threonine
phosphorylation [27]. And for many years, it was believed
to be a constitutively active kinase; however, it has become
apparent that the activity of GSK-3 may be regulated by a
variety of means. In fact, control of GSK-3 activity occurs by
complex mechanisms that are each dependent upon specific
signalling pathways. Thus, the regulatory mechanisms can be
classified as follow.
3.1. Regulation by Phosphorylation. The first regulatory
mechanism described of GSK-3 activity involved the phos-
phorylation of specific residues of GSK-3 by other kinases,
and more recently through autophosphorylation [17, 28].
Four diﬀerent regions and residues have been described
in the GSK-3 molecule. The first one corresponds with a
serine residue at positions 21 in GSK-3α and 9 in GSK-3β. It
has been clearly established that phosphorylation of serine 21
or 9 correlates with the inhibition of its kinase activity [29–
31]. Many protein kinases are capable of phosphorylating
GSK-3 at this residue, such as Akt, ILK, PKA, and p90Rsk
[32, 33], and many physiological situations of inhibition
of GSK-3 correlate with serine phosphorylation, such as
Insulin/IGF1, NGF, or estradiol treatments, not only in
neurons [34].
Additionally, two other regulatory sites have been
described. One is the threonine 43, present only in the
isoform GSK-3β, which may be phosphorylated by Erk [35].
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This phosphorylation correlated with GSK-3 inhibition.
Second, serine 389 and threonine 390 present in GSK-3β
have been shown to be phosphorylated by p38 MAPK [36].
In both cases, the data suggested that this phosphorylation
may increase the capacity of Ser-9 to be phosphorylated
rather than promote a direct inhibition (see Figure 1).
In contrast, tyrosine phosphorylation present in posi-
tions 279 in GSK-3α or 216 in GSK-3β, appears to correlate
with an increase of its kinase activity [37]. Diﬀerent candi-
dates such as Pyk-2 and Fyn kinases have been reported to
be able to phosphorylate GSK-3 in vitro on tyrosine. In addi-
tion, MEK1/2 has been showed to have this capacity only in
fibroblasts [38, 39]. This data contrast with those reported in
Dictyostelium discoideum where there is compelling evidence
indicating that ZAK 1 is responsible for generating tyrosine
phosphorylation in GSK-3 [14, 40]. However, no homologue
of such kinase has been found in mammals.
More recently, an alternative hypothesis has been pro-
posed for the regulation of GSK-3 tyrosine phosphoryla-
tion. This hypothesis suggests that in mammalian systems
phosphotyrosine in GSK-3 corresponds to an intramolec-
ular autophosphorylation event and may be regulated
by Hsp90 [41]. Molecular dynamics and crystallographic
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studies clearly suggest that Tyr216 renders the kinase active
through interactions with Arg220 and Arg223, stabilizing
the activation loop and allowing full substrate accessibility
[42, 43]. However, this hypothesis still lacks a cellular
demonstration.
However, our data indicated that not all pharmacological
inhibitors of GSK-3 decrease the level of phosphotyrosine.
Therefore, lithium chloride inhibits GSK-3 activity, but this
inhibition does not alter its pTyr content [44]. Moreover, in
neuronal cells, tyrosine phosphorylation of residue 216 or
279 increased following exposure to LPA [37] and even upon
exposure of neurons to β-amyloid or PrP [13, 45, 46] in a
clear correlation with an increase in GSK-3 activity. In addi-
tion, in many neuronal cells, the pharmacological inhibition
of tyrosine phosphatases with ortho-vanadate increases the
basal level of GSK-3-pTyr [44]. Thus, considering all these
data, in addition to this tantalizing autoregulatory system
proposed, we hypothesized that some as-yet-unidentified
tyrosine kinases and phosphatases may also regulate this
kinase (see Figure 2).
3.2. Regulation by Protein Complex Association. One regula-
tory mechanism that is still not fully understood involves the
interaction of the GSK-3 with structural proteins (scaﬀold
proteins). It is well known that GSK-3 contributes to a
multiprotein complex formed by axin and adenomatous
polyposis coli (APC), among others (for review see, i.e.,
[47]). This protein complex is the core of canonical Wnt
signalling (see below). Indeed, in the absence of ligand,
GSK-3 is able to phosphorylate β-catenin for targeting it
for proteasome degradation [48]. More recently, some data
suggests that this complex may be specific for GSK-3β2
isoform [49], which opens the possibility of a deeper analysis
of “specific functions of GSK-3 isoforms.”
Another system of protein-kinase interaction was
denoted as GSK-3-binding protein (GBP or FRAT) [25, 50].
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Three diﬀerent FRATs have been cloned and characterized;
however, their mechanism of action is not well understood.
FRAT1 appears to act as an inhibitory system [51], whereas
FRAT2 appears to preferentially increase GSK-3-mediated
phosphorylation in some residues [52]. Surprisingly, recent
data demonstrated that FRAT is dispensable because the
triple FRAT-knockout mouse lacks any major defect in brain
development [53]. All these data indicated that the precise
role of FRAT in GSK-3 regulation is still to be defined.
Using the binding site on GSK-3 for FRAT/GBP, a GSK-
3-interacting protein symbolized by GSKIP has been cloned
and characterized. GSKIP can block phosphorylation of
diﬀerent substrates and functions as a negative regulator of
GSK-3 beta [54].
3.3. Regulation by Priming/Substrate Specificity. As previ-
ously mentioned, the specificity of many kinases is governed
by a consensus sequence of aminoacids sequence. However,
as almost general rule, GSK-3 substrates do not require a
very specific sequence, but a previous (primed) phospho-
rylation residue modified by a priming kinase located four
aminoacids, C-terminal, to the Ser or Thr residue to be
modified by GSK-3. The crystal structure of human GSK-
3β provides a model for the binding of prephosphorylated
substrates to the kinase (PDB ID are 1I09 [22] and 1H8F
[21]). According to it, primed Ser/Thr is recognized by
a positively charged binding pocket formed by residues
Arg96, Arg180, and Lys205 that facilitates the binding of the
phosphate group of primed substrates.
Some “priming kinases” have been identified, such as
cdk-5 [55–57], PAR-1 [58], casein kinase I [59], PK-C [60],
or PK-A [57]. However, it is not clear so far whether a second
set of “nonprimed” substrates may define a diﬀerent group
of functions [61]. In addition, diﬀerent glycogen synthase
kinase-3 isoforms appear to exhibit distinct substrate pref-
erence in the brain [62].
3.4. Regulation by Subcellular Localization. In developmental
brain, the presence of GSK-3 was high at E18 and peaked
on P8, decreasing after that period [63]. In addition, this
report showed that the developmental profile of GSK-3α
and GSK-3β is diﬀerent, having β downregulated after birth
which suggested a diﬀerential role in neuronal development.
However, the putative diﬀerential role of each isoform has
been explored in few reports, that is, [7]. It is important to
indicate that a portion of GSK-3, mostly β, has been reported
to be associated in the growth cone. This GSK-3 pool appears
to respond rapidly, being modified by phosphorylation
and/or relocated in the growth cone by external signals such
as Semaphorins [64] or NGF [65].
GSK-3 activity is also dependent on its subcellular
localization; some data illustrated the presence of GSK-3α
and β in many neuronal compartments and in primary
neurons, either in axon, dendrite, or in nucleus [66, 67]. In
addition, GSK-3 has been found in the cytoplasm, nucleus
and the mitochondria [18]. Considering the list of GSK-
3 substrates reported, it is evident that most of its activity
should occur in the cytoplasm and in the nucleus, while we
have less information about GSK-3 potential targets in the
mitochondria. Recent data suggested that proteins such as
Mcl-1 [68] and hexokinase [69] may be regulated by GSK-
3 activity. It has been suggested that nuclear GSK-3 may be
involved in phosphorylation of many transcription factors
such as cyclin D1, β-catenin, HSF-1, NFAT, and cAMP-
response element-binding protein, among others (Table 1),
for review see [28, 70, 71]. Also, it has been proposed that
GSK-3 in the nucleus may have a role in alternative splic-
ing [72]. In addition, proapoptotic stimuli induce nuclear
accumulation of GSK-3β [73]; however, this hypothesis has
been not established in other neuronal death paradigms (D.
Simon, unpublished observations).
Further insight into GSK-3 regulation has been gained
very recently by revealing an essential role of multivesicular
endosomes in the Wnt signalling pathway. A combination of
protease protection assays, detergent permeabilization, and
cryoimmunoelectron microscopy demonstrated that Wnt
activation of the Frizzled and LRP6 receptors triggers seques-
tration of GSK-3 into these membrane-bounded organelles,
leading to decreased GSK-3 levels in the cytosol [74]. This
process seems to require β-catenin, forming a feed-forward
loop by facilitating GSK-3 sequestration.
3.5. Regulation by Proteolytic Cleavage. A new mechanism
of GSK-3 regulation has been recently proposed. This reg-
ulation involves the removal by calpain of a fragment from
the N-terminal region of GSK-3, including the regulatory
serines 9/21. After removal of that fragment, GSK-3 becomes
activated [75]. The same study showed that both isoforms
α and β are cleaved by calpain, although with diﬀerent sus-
ceptibility. Moreover, GSK-3 truncation has been observed
in human and mouse postmortem brain tissue [76]. It is
noteworthy to consider that a similar mechanism has been
described for β-catenin in hippocampal neurons, where after
NMDA-receptor-dependent activation, calpain induced the
cleavage of β-catenin at the N terminus, generating stable and
truncated forms which maintain its transcriptional capacity
[77]. Likewise, GSK-3 truncation is mediated by extracellular
calcium and can be inhibited by memantine [76], an NMDA
antagonist used for the treatment of Alzheimer’s disease.
Interestingly, GSK-3β has also been recently shown to be
cleaved at the N-terminus (and subsequently activated) by
matrix metalloproteinase-2 (MMP-2) in cardiomyoblasts
[78].
4. Pathways Controlling GSK-3
Activity in Neurons
The regulation of GSK-3, as previously mentioned, is
an essential regulatory key controlling many physiological
processes in neurons. Many external signals may trigger
pathways that finally may activate or inhibit GSK-3 activity,
either transiently or in more sustained way. These “physio-
logical pathways” could be subdivided in two major clusters,
those that essentially have to inhibit GSK-3 activity, and
second, those that may, at least transiently, trigger GSK-3
activity.
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4.1. Inhibitory Pathways. Among these pathways, the sig-
nalling triggered by Insulin or IGF-1 [19, 79, 80] and
NGF/BDNF/NT3 [81, 82] has similar features. These tyro-
sine kinase receptors initiated cytoplasm signals in which
the inhibition of GSK-3 activity is a common feature. It
is generally accepted that the kinase implicated in this
inhibition is PKB/Akt [29–31], even though kinases such
as PKA or ILK have also been implicated [32, 33]. In all
cases, phosphorylation on serine 21 and 9 (α and β, resp.)
represents the inhibition of the GSK3 kinase activity, as
previously mentioned.
The second well-documented pathway is Wnt/Wingless
signalling [83, 84]. This signalling has been widely studied,
and it has been shown to be essential in early embryonic
patterning, cell fate, cellular polarity, and cell movement in
both vertebrates and invertebrates [47, 85]. In many if not
all cell systems, the canonical Wnt pathway is formed by a
set of phylogenetically conserved proteins including the Wnt
receptor frizzled (fz), and a coreceptor LRP5/6; Dishevelled
(Dsh), and a scaﬀolding protein that activates a complex
formed by Axin/APC/GSK3-β/β-catenin [47, 85–88].
In this pathway, in the absence of ligand, GSK-3β phos-
phorylates β-catenin, among other proteins, this phosphory-
lation constituting part of a degradation signal for β-catenin.
However, in the presence of Wnt, the receptor complex
triggers a signal in which Dsh inhibits the activity of GSK-
3β by a mechanism not completely understood, so far. This
system appears to be specific for GSK-3β as no counterpart
has been described for GSK-3α to date; however, some GSK-
3 activity appears to be necessary for Wnt signalling [89, 90].
More recently, a bioinformatics-based screen for proteins
whose stability may be controlled by GSK-3 [91] has led to
the identification of a number of multiple Wnt signalling
target proteins, suggesting that this pathway controls a
broad range of cellular activities apart form β-catenin-
mediated transcriptional activation. Furthermore, GSK-3-
mediated Wnt signalling seems to regulate the turnover
of many cellular proteins [74, 91], indicating that GSK-
3 phosphorylation-dependent protein degradation may be
a widespread cellular mechanism to regulate a variety of
cellular processes in response to extracellular signals [71].
Functional segregation of the insulin/growth factor
and Wnt roles requires either that there be no exchange
between the subsets of the cellular GSK-3β pool committed
to each role, or that the recruitment of GSK-3β to the
axin-APC complex can reverse or override inhibitory Ser9
phosphorylation present in a recruited GSK-3β molecule.
Phosphatases capable of removing extant Ser9 phosphory-
lation are certainly known to be associated with the axin-
APC complex [92, 93]. Alternatively, the very substantial
enhancement in activity towards β-catenin aﬀorded by the
axin “scaﬀolding” may simply allow a primed β-catenin
substrate to outcompete a pSer9-GSK-3βN-terminal peptide
for access to the substrate-binding site [26].
Estrogens regulate many physiological processes and
fulfil a wide range of functions during development and
diﬀerentiation in mammals of both sexes. The actions of
estrogens are mediated by estrogen receptors and have been
classified as either “genomic actions” or “nongenomic, rapid
actions.” The genomic actions are based on the capacity
of the estrogen receptors (ERs) to modulate transcriptional
activity either directly or through coactivators or corepres-
sors, that is, [94, 95].
More recently, it has been shown that in addition to
its direct transcriptional activity, estrogen receptors activate
a set of cytoplasm signals in a similar manner to some
growth factors. Hence, it has been reported that estradiol
acts synergistically with IGF-1 in the brain or in neurons,
activating the PI3K/Akt pathway [34, 96, 97]. We described
that the addition of estradiol increases the serine phospho-
rylation of GSK-3. This inhibitory phosphorylation is time-
and concentration dependent, and an antagonist of estradiol
prevents this event. The kinase responsible is sensitive to
the inhibition of the PI3K pathway, and for this reason,
it seems that the best candidate would be Akt [98, 99]. A
more detailed analysis of these new signals will give us clear
evidence whether this pathway is completely convergent with
those using PI3K/Akt/GSK3, as previously mentioned.
4.2. Activation Pathways. In neurons, LPA has been shown
to induce neurite retraction and the rounding up of neu-
roblastoma cell lines [100]. In some primary neurons, it
also promotes growth cone collapse and neurite retraction
[37, 101]. This bioactive lipid acts as a growth factor through
specific seven transmembrane domain receptors, denoted
as lpa 1–4 [102, 103]. We described that GSK3 activity
was increased after LPA treatment in diverse neuronal
cells of diﬀerent species in correlation with the neurite
retraction process [104, 105]. This activation correlated with
an increase in GSK3-PTyr and may be downstream Gα12
or Gα13 [101, 105, 106]. The previous inhibition of GSK3
activity prevents, at least in part, the growth cone collapse
response. Similarly, it has been reported that three diﬀerent
GSK-3 antagonists (LiCl, SB-216763, and SB-415286) can
inhibit the growth cone collapse response induced by Sema
3A [64].
However, the exact mechanism of how this activation of
GSK3 occurs is not known, so far. Many reports indicate
that inDictyostelium discoideum GSK-3 activity may increase
in response to cAMP binding to a heptahelical G-protein-
coupled receptor. In this system, a tyrosine kinase and a
tyrosine phosphatase have been described as regulators of
GSK-3 activity [14, 40], but similar kinase and phosphatase
have not been found in mammals.
Furthermore, it has been reported that Reelin and Netrin
increased GSK-3 activity, similar to what LPA did. This
Netrin or Reelin-dependent GSK-3 activation seems not
to be a particular characteristic of the cell line or neuron
used but rather a more general physiological process [107–
109]. Indeed, even in situations where the final balance is
an inhibition of GSK-3 kinase activity, such as following
the addition of IGF1/Insulin or after estradiol addition, a
transient activation of GSK-3 could be observed [34, 38]. All
these data suggest that the upregulation and downregulation
of this kinase is more complex than might initially have been
considered.
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5. Pathological Activation of GSK-3
Deregulation of GSK-3 has been linked to a wide range of
human pathological conditions including type II diabetes,
muscle wasting, cancer and neurological disorders such as
bipolar disorder, schizophrenia, depression, stroke, sleep
disorders, and Alzheimer’s disease (AD), among others, for
a review see [110].
Lithium and valproic acid are mood stabilizers widely
used in the chronic treatment of bipolar disorders. Lithium
ions directly inhibit GSK-3 [111], most likely by competing
with magnesium [112], while valproic acid is able to inhibit
GSK-3 activity in relevant therapeutic concentrations in
human neuroblastoma cells [113] although in vivo direct
inhibition of GSK-3 by valproic acid remains a matter of
debate [114]. The precise mechanism of action by which
lithium exerts its therapeutic eﬀects is not known, but it is
conceivable that the acute eﬀects on GSK-3 result in changes
in gene regulation and cellular changes which could aﬀect
the neuronal plasticity over time [115]. Actually, lithium
is also an inhibitor of several phosphomonoesterases [116]
and phosphoglucomutases [117], but the fact that GSK-3
has been shown to be significantly inhibited at therapeutic
lithium concentrations [118–120] suggests that at least a
significant proportion of lithium’s therapeutic actions in
bipolar disorder results from the inhibition of GSK-3,
underlying its importance as a therapeutic target for this
disorder [121, 122].
Lymphocytes of patients with schizophrenia show
impaired GSK-3 protein levels and activity [123], whereas
GSK-3 has been reported to be reduced in the frontal
cortex of postmortem schizophrenic brains [124]. Since the
Wnt family of genes plays a central role in normal brain
development, it is possible that GSK-3 impairment may
lead to abnormal neuronal development. More recently, a
direct association has been shown between GSK-3 and the
N-terminal region of disrupted-in-schizophrenia-1 (DISC1),
a strong genetic risk factor associated with schizophrenia
[125]. Moreover, mounting evidence suggests that GSK-3
is a crucial node that mediates various cellular processes
that are controlled by multiple signalling molecules such
as DISC-1, PAR3, PAR6, and Wnt proteins that regulate
neurodevelopment [88].
Interestingly, increased levels of GSK-3 have also been
reported in postmortem analysis of brains from AD patients
compared to age-matched control samples [126], whereas
a spatial and temporal pattern of increased active GSK-
3β expression correlates with the progression of NFT and
neurodegeneration [127]. Apart from being the major kinase
to phosphorylate tau both in vitro and in vivo [128], GSK-3
has been recently proposed as the link between the twomajor
histopathological hallmarks of AD, the extracellular amyloid
plaques and the intracellular NFT [129, 130].
Exposure of primary neuronal cultures to Aβ induces
activation of GSK-3 [131], tau phosphorylation [132], and
cell death [133, 134], whereas blockade of GSK-3 expression
by antisense oligonucleotides or its activity by lithium
inhibits Aβ-induced toxicity [135, 136]. GSK-3 inhibition
per se decreases Aβ production in cells and in an animal
model of amyloidosis [61, 120], most likely through amecha-
nism involving inhibition of γ-secretase [137]. Furthermore,
amyloid precursor protein (APP) itself is a substrate for
GSK-3 in vitro and in vivo [138]. Finally, modulation of the
GSK-3 signalling pathway by chronic lithium treatment of
transgenic animals might also have neuroprotective eﬀects by
regulating APP maturation and processing [138].
In tauopathies such as frontotemporal dementia with
Parkinsonism (FTDP) linked to chromosome 17, the pres-
ence of some mutations in tau protein correlates with the
onset of the disease [139, 140]. Treatment of transgenic mice
overexpressing mutant human tau (P301L, 4RON), with the
GSK-3 inhibitor lithium, has been shown to significantly
decrease the levels of tau phosphorylation and significantly
reduce the levels of aggregated, insoluble tau. Administration
in this model of a second GSK-3 inhibitor, AR-A014418, also
correlated with reduced insoluble tau levels, supporting the
notion that lithium exerts its eﬀect through GSK-3 inhibition
[23]. More recently, chronic lithium administration has also
been shown to reduce tau phosphorylation in the 3xTg-AD
mice [141], but did not significantly alter the amyloid load.
An increase in GSK-3 activity has also been shown to
coincide with cell death following middle cerebral artery
occlusion in mice which results in cortical infarcts [142],
and a reduction in infarct volume with the GSK-3 inhibitor
lithium was demonstrated [143], indicating that GSK-3 inhi-
bition may be beneficial in stroke. In fact, pharmacological
inhibition of GSK-3 reduced infarct volume and improved
behaviour in a focal cerebral ischemia model [144].
6. GSK-3 as a Therapeutic Target
Besides deregulation of its activity in neurodegenerative
processes, mounting evidence further suggests a potential
role for GSK-3 as a therapeutic target in a range or other
pathologies, including pancreatic cancer [145], parenchymal
renal diseases [146], and HIV-1-associated dementia [147],
among others.
The recent discovery that glycogen synthase kinase-3
(GSK-3) promotes inflammation through nuclear factor
kappa B (NFκB) has revealed new functions on regulating
inflammatory processes [148]. Furthermore, GSK-3 inhi-
bition provides protection from inflammatory conditions
in diﬀerent animal model [149], suggesting that GSK-3
inhibitors may have multiple eﬀects influencing these con-
ditions.
Finally, recent developments suggest an active role of
GSK-3β in various human cancers, although its role in
tumourigenesis and cancer progression remains controver-
sial. It may function as a “tumour suppressor” for certain
types of tumours, whereas it seems to promote growth
and development for some others. Deregulation of GSK-
3β has been shown to promote gastrointestinal, pancreatic,
and liver cancers and glioblastomas. Furthermore, GSK-3β
inhibition attenuates cell survival and proliferation, induces
cell senescence and apoptosis, and sensitizes tumour cells to
chemotherapeutic agents [150] and ionizing radiation [151].
Nevertheless, an attractive target for a variety of human
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diseases, its therapeutic potential on tumourigenesis, and
cancer chemotherapy still needs to be carefully evaluated
[152].
The close involvement of GSK-3 activity in diﬀerent
human pathologies has sparked intense eﬀorts in developing
inhibitors as therapeutic agents. Thus, the discovery of small
molecule GSK-3 inhibitors in the last few years has not only
attracted significant attention to the protein as a therapeutic
target but also has provided a means to further understand
the physiological functions of GSK-3 and to gain further
insight into the molecular basis of those disorders.
In fact, at least one small molecule GSK-3 inhibitor
program has made it to the clinic [153]. Tideglusib (NP-
12) is a synthetic small molecule form the TDZD chemical
class [110] which is currently in phase II development for
two CNS indications: Alzheimer’s disease and progressive
supranuclear palsy (PSP), a tauopathy [154].
7. Conclusion
Three decades after its discovery as a protein kinase involved
in glycogenmetabolism, GSK-3 was revealed as a key enzyme
in regulating many critical cellular processes, providing a
link betweenmany diﬀerent substrates and various signalling
pathways as well as gene expression. Modulation of its
activity has also turned out to be much more complex than
originally thought, as evident from what has been reviewed
here. Furthermore, its role in a variety of highly relevant
human pathological conditions has drawn significant atten-
tion to this enzyme as a potential therapeutic target, and the
recent development of specific inhibitors has granted us new
tools to dissect out its molecular and physiological functions
while providing novel therapeutic agents. Taken all together,
the next few years will certainly bring us further insights into
the cellular functions of this fascinating enzyme.
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